Cancer investigators led by researchers at Vanderbilt-Ingram Cancer Center (VICC) have co-developed a liquid biopsy blood-based assay used to identify specific gene mutations associated with the development or relapse of small-cell lung cancer (SCLC).

Vanderbilt-Ingram Cancer Center (VICC) will sponsor an educational conference for kidney cancer patients, survivors and family members Saturday, Sept. 9, 8 a.m. – 2 p.m., in the Preston Research Building, Suite 898.

An international genomic data-sharing consortium has analyzed nearly 19,000 patient genomic records and found that testing of patient tumors for relevant gene mutations often provides a roadmap for the use of effective therapies.

Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology at Vanderbilt, has been elected to The American Society for Clinical Investigation (ASCI).

W. Kimryn Rathmell, director of the Division of Hematology/Oncology at Vanderbilt University Medical Center, has been named vice president of The American Society for Clinical Investigation.

Several investigators in Vanderbilt-Ingram Cancer Center’s (VICC) Breast Cancer Program have received grant awards to support translational research that may improve disease outcomes for patients.